CRY2 — Your Circadian Glucose Regulator
Cryptochrome 2 (CRY2) is a core component of the
molecular circadian clock | The transcription-translation feedback loop
that generates ~24-hour rhythms in virtually every cell, governing
sleep-wake cycles, hormone release, and metabolism.
Like its partner CRY1, CRY2 acts as a transcriptional repressor that
shuts down the CLOCK:BMAL1 complex — but CRY2 has a distinct role in
metabolism. The rs11605924 variant was identified in the landmark
MAGIC consortium GWAS | Meta-analysis of 21 genome-wide association
studies in 46,186 non-diabetic participants
as one of nine new loci associated with fasting glucose, placing CRY2
at the intersection of circadian biology and metabolic disease.
The Mechanism
CRY2 encodes a flavin adenine dinucleotide (FAD)-binding protein |
The FAD cofactor is essential for CRY2's light-independent repressor
function in mammals, distinguishing it from light-sensing cryptochromes
in other organisms that forms repressive complexes with PER proteins
to suppress CLOCK:BMAL1-driven transcription. This feedback loop
generates rhythmic expression of thousands of metabolic genes,
including those controlling
hepatic glucose production | CRY proteins directly regulate
gluconeogenic gene expression through interaction with the glucocorticoid
receptor and FOXO1 transcription factors and insulin secretion.
The rs11605924 variant sits within an intron of CRY2 on chromosome 11.
While intronic, the variant appears to affect CRY2 expression or
splicing efficiency, as carriers show measurable differences in both
glucose homeostasis and hepatic lipid handling. CRY2 is expressed
rhythmically in the liver, pancreatic beta cells, and adipose tissue,
all key sites of glucose regulation.
A fascinating finding links this variant to hepatic metabolism:
Machicao et al. 2016 | Machicao F et al. Glucose-Raising Polymorphisms
in the Human Clock Gene Cryptochrome 2 (CRY2) Affect Hepatic Lipid
Content. PLoS One, 2016
showed that the glucose-raising alleles concomitantly reduced liver fat
content by approximately 30%, suggesting that the variant redirects
intermediary metabolites from hepatic triglyceride synthesis toward
gluconeogenesis. This metabolic shunting effect explains how the same
variant can raise fasting glucose while paradoxically reducing fatty
liver.
The Evidence
The MAGIC consortium GWAS | Dupuis J et al. New genetic loci
implicated in fasting glucose homeostasis and their impact on type 2
diabetes risk. Nat Genet, 2010
identified rs11605924 among nine new fasting glucose loci in a
meta-analysis of 46,186 non-diabetic individuals, with follow-up in
76,558 additional subjects. CRY2 was the only core circadian clock
gene among these loci, providing the first direct genetic link between
the circadian machinery and population-level glucose variation.
The GLACIER Study | Renstrom F et al. Season-dependent associations
of circadian rhythm-regulating loci and glucose homeostasis.
Diabetologia, 2015 from
northern Sweden revealed a remarkable finding: the association between
rs11605924 and 2-hour glucose levels (beta = 0.07 mmol/L per A allele,
P = 0.0008, n = 9,605) was present only during the dark season
(P for interaction = 0.006). During the light season, no association
was detected. This season-dependent effect is biologically plausible:
CRY2 is a light-responsive clock protein, and extreme photoperiod
variation in northern latitudes may unmask its metabolic effects.
In the hepatic lipid study | Machicao et al. 2016,
four CRY2 SNPs including rs11605924 showed study-wide significant
associations with fasting glucose (P < 0.0005) and concomitant
associations with liver fat content (P < 0.015) in 1,715 non-diabetic
individuals. In vivo MRS measurements in 375 subjects confirmed
approximately 30% reduced liver fat in carriers of the glucose-raising
alleles.
Replication in non-European populations came from
Liu et al. 2011 | Liu C et al. Variants in GLIS3 and CRY2 Are
Associated with Type 2 Diabetes and Impaired Fasting Glucose in
Chinese Hans. PLoS One, 2011,
where the A allele was associated with combined impaired fasting
glucose and type 2 diabetes (OR 1.15, 95% CI 1.01-1.30, P = 0.04)
in 3,210 Chinese participants, though this association was attenuated
after adjustment for additional confounders.
The POUNDS LOST Trial | 2014
demonstrated that CRY2 rs11605924 influenced metabolic responses to
weight-loss diets, with significant associations between genotype and
changes in respiratory quotient, resting metabolic rate, and energy
expenditure during a 2-year intervention, suggesting the variant
modulates how effectively different dietary strategies work.
Practical Implications
The CRY2 variant affects glucose regulation through a circadian
mechanism, which means its metabolic consequences are amplified by
circadian disruption — shift work, irregular meal timing, jet lag,
or insufficient light exposure. Carriers of the risk allele who
maintain regular circadian rhythms may show minimal glucose
elevation, while those with disrupted rhythms may see larger effects.
The seasonal modulation of the glucose effect suggests that
latitude and light exposure are modifiers. People in northern
latitudes carrying the A allele may benefit from light therapy
during dark winter months to stabilize their circadian-metabolic
coupling.
Interactions
CRY2 operates in the same circadian feedback loop as CRY1
(rs2287161), CLOCK (rs1801260), and MTNR1B (rs10830963).
The GLACIER Study tested interactions between these loci and found
season-dependent effects for all three circadian variants (CRY1,
CRY2, MTNR1B), suggesting they converge on a shared
photoperiod-sensitive metabolic pathway. Carriers of glucose-raising
alleles at multiple circadian loci may show amplified seasonal
glucose variation.
Compound implication for CRY2 rs11605924 + MTNR1B rs10830963:
Both variants affect circadian glucose regulation — MTNR1B through
melatonin-mediated suppression of insulin secretion, CRY2 through
transcriptional control of gluconeogenic genes. Carriers of the
risk allele at both loci may show the strongest seasonal glucose
fluctuation and the greatest benefit from stabilizing circadian
rhythms during dark months. They should consider monitoring fasting
glucose in both summer and winter to detect seasonal variation.
All Genotypes
Normal CRY2-mediated circadian glucose regulation
You have two copies of the C allele, which is associated with lower fasting glucose and standard circadian regulation of hepatic glucose production. About 16% of people globally share this genotype, though it is more common in European populations (approximately 28%). You do not carry the glucose-raising CRY2 variant.
One copy of the glucose-raising allele with modest circadian metabolic impact
You carry one copy each of the A and C alleles. The A allele modestly raises fasting glucose through altered CRY2-mediated circadian regulation of the liver. About 47% of people share this genotype. The metabolic effect is smaller than in AA homozygotes and may only become apparent during dark winter months or with disrupted circadian rhythms.
Two copies of the glucose-raising allele with maximal effect on circadian glucose regulation
You have two copies of the A allele at CRY2 rs11605924, which raises your baseline fasting glucose through altered circadian regulation of hepatic glucose production. About 37% of people globally share this genotype. The effect is modest in absolute terms but consistent across multiple large studies, and it may be amplified during dark winter months or with irregular circadian rhythms.